P-1532. Surveillance of Eravacycline Against Clinical Pathogens, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022

Abstract Background Eravacycline is a fully synthetic, fluorocycline antibiotic approved for the treatment of complicated intra-abdominal infections (cIAI) in patients ≥18 years of age in Europe, Singapore, China, Taiwan, Hong Kong, the US and the UK. The purpose of this study was to monitor the in vitro activity of eravacycline against isolates collected from a global surveillance study from 2018-2022. A total of 35,336 isolates were collected of which data for 23,127 isolates comprising Staphylococcus aureus (including methicillin-resistant S. aureus, MRSA), Enterococcus spp. (including vancomycin-resistant Enterococcus, VRE) and Streptococcus spp., Enterobacterales (C. freundii, E. cloacae, E. coli, K. oxytoca and K. pneumoniae) and non-fermenters are reported. Methods A total of 23,127 clinical isolates were collected during 2018-2022 from multiple infection sources, including, IAI, body fluids, blood, gastrointestinal, genitourinary and respiratory. The isolates were from Asia/Pacific (n=4,812), Europe (n=9,606) and North America (n=8,709). Minimum inhibitory concentrations (MICs) were determined by CLSI broth microdilution. For comparative purposes, isolate susceptibility for eravacycline and tigecycline was determined with both FDA and EUCAST breakpoints, where available. Results Summary MIC data for eravacycline and tigecycline as a selected comparator are shown in the Table. Susceptibility to eravacycline in all Gram-positive pathogens were greater than 90% for most species /phenotypes though was notably higher when EUCAST breakpoints were applied to the analysis. For Enterobacterales, eravacycline susceptibilities were consistently >93% though MDR susceptibility was slightly lower (84.2% susceptible to eravacycline). Conclusion Eravacycline demonstrated sustained high activity rates against clinically important pathogens. Importantly, the MIC90 and susceptibilities did not change over time and were similar for the different geographical regions. Disclosures Sherry Siegert, PharmD, Innoviva Specialty Therapeutics: Stocks/Bonds (Public Company)|Innoviva Specialty Therapeutics, Inc.: Employee Kristie Zappas, PharmD, Innoviva Specialty Therapeutics, Inc.: Employee Sarah McLeod, PhD, Innoviva Specialty Therapeutics: Employee|Innoviva Specialty Therapeutics: Stocks/Bonds (Public Company) Samir H. Moussa, PhD, Innoviva Specialty Therapeutics: Employee|Innoviva Specialty Therapeutics: Stocks/Bonds (Public Company)